natgillin/translations-raw huggingface dataset:
A novel pharmaceutical composition according to claim 1-3, wherein lactose monohydrate is present in the core in a proportion of 30 - 60%. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 1-2, naznačen time što je monohidrat laktoze prisutan u jezgri u udijelu od 30-60%.
Use of a pharmaceutical composition according to any of claims 14 to 21 as an anti-cancer vaccine. 
Korištenje farmaceutskog sastava sukladno bilo kojoj od tvrdnji 10 do 16 za pripremu cjepiva protiv raka.
The mixture was extracted with dichloromethane (3 x 1L) and the combined organic phase passed through a silica plug (500 g) eluting with further dichloromethane (1 L) and 10% ethyl acetate in dichloromethane (1 L). 
Smjesu se ekstrahira diklormetanom (3 x 11), a pomiješanu organsku fazu propusti kroz čep od silicijevog dioksida (500 g), uz eluiranje s još diklormetana (1 1) i 10 % etil-acetata u diklormetanu (1 1).
The monoclonal antibody of claim 4, which is humanized. The monoclonal antibody of claim 7, which comprises VH and VL chains having amino acid sequences of: 
Monoklonalno antitijelo iz patentnog zahtjeva 6 naznačeno time da sadrži VH i VL lance koji imaju sekvencije odabrane iz jedne od sljedećih skupina VH i VL sekvencija:
The pharmaceutical composition according to claim 1, comprising 150.00 mg of Capecitabine, 4.28 mg of Hypromellose, 75.01 mg of Crospovidone, 70.75 mg of Mannitol, 98.71 mg of Microcrystalline Cellulose, 8.90 mg of Magnesium Stearate, 18.64 mg of Aspartame, 3.86 mg of Saccharin Sodium, 9.43 mg of Vanillin, 1.76 mg of Bittermasking Blend and 3.56 mg of Strawberry Flavor. 
Farmaceutski sastav prema zahtjevu 1, naznačen time, da sadrži 150,00 mg kapecitabina, 4,28 mg hipromeloze, 75,01 krospovidona, 70,75 mg manitola, 98,71 mg mikrokristalinične celuloze, 8,90 mg magnezij stearata, 18,64 mg aspartama, 3,86 mg natrij saharina, 9,43 mg vanilije, 1,76 mg smjese za maskiranje gorčine i 3,56 mg arome jagode.
The compound according to claim 1, wherein Ra represents a hydrogen atom or a methyl group. 
Spoj formule (I) u skladu s patentnim zahtjevom 1, naznačen time, da Ra predstavlja atom vodika ili metilnu skupinu.
A pharmaceutical composition comprising the compound of claim 6 or claim 7 and a pharmaceutically acceptable diluent or carrier. 
Farmaceutski spoj koji sadrži spoj iz bilo kojeg od zahtjeva od 1 do 7 i farmaceutski prihvatljiv razrjeđivač ili nosač.
These data demonstrate the immunosuppressive activity of 42-O-(D-Fructosylcarbonyl)rapamycin in preventing graft rejection. 
Ovi podaci pokazuju imunosupresivnu aktivnost 42-0-(D-fruktozilkarbonil)rapamicina u sprečavanu odbacivanja transplantata.
These openings have preferably a diameter smaller than 5 mm and more particular about 2 mm. 
Poželjno je da ti otvori imaju promjer manji od 5 mm i još poželjnije oko 2 mm.
The method of claim 5 or 6, wherein the matrix is selected from the group consisting of: laminin, fibronectin, vitronectin, proteoglycan, entactin, collagen, collagen I, collagen IV, heparan sulfate, a soluble preparation from Engelbreth-Holm-Swarm (EHS) mouse sarcoma cells, a human basement membrane extract, and any combination thereof. 
Postupak u skladu s patentnim zahtjevom 5 ili 6, naznačen time što se matriks bira iz skupine koju čine: laminin, fibronektin, vitronektin, proteoglikan, entaktin, kolagen, kolagen I, kolagen IV, heparan-sulfat, topljivi pripravak iz stanica mišjeg Engelbreth-Holm-Swarm (EHS) sarkoma, ekstrakt ljudske bazalne membrane, te bilo koja njihova kombinacija.
The pharmaceutical composition of claim 3, wherein the steroidal anti-inflammatory agent is a corticosteroid or a pharmaceutically acceptable salt or solvate thereof. 
Farmaceutski pripravak iz patentnog zahtjeva 5, naznačen time, da je steroidno protu-upalno sredstvo kortikosteroid ili njegova farmaceutski prihvatljiva sol ili solvat.
A packaging according to claim 12, wherein the two hinges defines a groove on a backside of the packaging, said grooves being adapted to engage with corresponding protrusions on the first and second outer part and/or metal layer/part for attaching these to the inner part. 
Pakiranje u skladu s patentnim zahtjevom 12, naznačeno time, što dva panta imaju utor na stražnjoj strani pakiranja, pri čemu su navedeni utori prilagođeni da zahvate odgovarajuća izbočenja na prvom i drugom vanjskom dijelu i/ili na metalnom sloju/dijelu radi pričvršćenja ovih na unutarnji dio.
A pharmaceutical composition comprising one or more oligomers of lactic acid as defined in any of claims 1-22 together with a pharmaceutically acceptable excipient, the composition being in the form of a a tampon, vagitorium, vaginal aerosol, vaginal cup, vaginal gel, vaginal, insert, vaginal patch, vaginal ring, vaginal sponge, vaginal suppository, vaginal cream, vaginal emulsion, vaginal foam, vaginal lotion, vaginal ointment, vaginal powder, vaginal shampoo, vaginal solution, vaginal spray, vaginal suspension, vaginal tablet, vaginal rod, vaginal shaum, vaginal disc vaginal semipermeable packaging and any combinatiön thereof. 
Farmaceutski pripravak koji sadrži jedan 1li više oligomera mliječne kiseline kao što je definirano u bilo kojem od patentnih zahtjeva 1-22, zajedno sa farmaceutski prihvatljivim ekscipijensom, pri čemu je pripravak u obliku tampona, vagitorija, vaginalnog aerosola, vaginalne šalice, vaginalnog gela, vaginalnog inserta, vaginalnog flastera, vaginalnog prstena, vaginalne spužve, vaginalnog čepića, vaginalne kreme, vaginalne emulzije, vaginalne pjene, vaginalnog losiona, vaginalne pomasti, vaginalnog pudra; vaginalnog šampona, vaginalne otopine, vaginalnog spreja, vaginalne suspenzije, vaginalne tablete, vaginalnog štapića, vaginalnog šauma, vaginalnog diska, semipropusnog materijala ili bilo koje kombinacije istih.
Because the preferred fuel element is relatively short, the hot, burning fire cone is always close to the aerosol generating means, which maximizes heat transfer thereto and maximizes the resultant production of aerosol, especially in embodiments which are provided with a heat conducting member. 
Zato što je poželjan gorivi element relativno kratak, vruć konus koji gori je uvijek blizak sredstvu za generiranje aerosola, što maksimira prijenos topline na njega i maksimira posljedičnu proizvodnju aerosola, naročito u realizacijama koje su osigurane sa članom za provođenje topline.
The tube also forms an aerosol delivery passage 26 between the aerosol generating means 12 and mouth end 15 of the article. 
Cijev 14 također formira prolaz 26 za provođenje aerosola između sredstva 12 za generiranje aerosola i usnog djela 15 proizvoda.
The method of claim 10, wherein the metabolic syndrome is selected from the group consisting of diabetes, obesity, nutritional disorders, organ atrophy, chronic obstructive pulmonary disease and anorexia. 
Upotreba u skladu s patentnim zahtjevom 7, naznačena time, da je metabolički sindrom odabran iz skupine koju čine dijabetes, pretilost, prehrambeni poremećaji, atrofija organa, kronična opstruktivna plućna bolest i anoreksija.
The method according to claim 2 wherein the water soluble polymer is PSA and wherein the PSA is prepared by reacting an activated aminooxy linker with oxidized PSA; wherein the aminooxy linker is selected from the group consisting of: a 3-oxa-pentane-1,5-dioxyamine linker of the formula: 
Postupak prema zahtjevu 2, pri čemu je polimer topljiv u vodi PSA i pri čemu je PSA pripremljen reagiranjem aktiviranog aminooksi veznika s oksidiranim PSA; pri čemu je aminooksi veznik odabran od skupine koja se sastoji od: a) 3-oksa-pentan-1,5-dioksiamin veznika formule: b) 3,6,9-trioksa-undekan-1, 11-dioksiamin veznika formule:
A pharmaceutical composition comprising the antibody of claim 13 and a pharmaceutically acceptable carrier. A kit comprising an antibody of any of the preceding claims comprising a therapeutically effective amount of an antibody of the invention, packaged in a container, said kit optionally containing a second therapeutic agent, and further comprising a label attached to or packaged with the container, the label describing the contents of the container and providing indications and/or instructions regarding use of the contents of the container to treat cancer, for example wherein the container is a vial or bottle or prefilled syringe. 
Komercijalno pakiranje koje sadrži antitijelo prema bilo kojem od Patentnih zahtjeva od 1 do 9, pakirano u terapijski efektivnoj količini u odgovarajuću posudu, pri čemu navedeno pakiranje može sadržati i drugi terapijski agens i dalje, može biti obilježeno etiketom zakačenom za ili upakiranom zajedno sa posudom u kojoj se nalazi antitijelo, pri čemu etiketa opisuje sastojke u posudi i pruža indikacije i/ili uputstva koja se odnose na upotrebu sastojaka za tretman raka; pakiranje može biti naznačeno i time, što posuda predstavlja bočicu ili bocu ili pak prethodno pripremljenu i napunjenu injekciju.
After 30 minutes, the pH value was increased to 2.3 by addition of alkali solution, after a further 90 minutes to pH 6.5 and after a further 60 minutes to pH 7.2. 
Nakon 30 minuta, dodatkom lužine je povećana pH-vrijednost na 2,3, nakon daljnjih 90 minuta na pH 6,5 i nakon još 60 daljnjih minuta na pH 7,2.
This synergistic activity is apparent from the fact that the fungicidal activity of the composition comprising component (A) and component (B) is greater than the sum of the fungicidal activities of component (A) and of component (B). 
Pripravak prema zahtjevu 1, naznačen time da je komponenta (A) 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-iljamid i komponenta (B) je odabrana od azoksistrobina i pikoksistrobina.
The reaction mass was stirred for 2.0 h. 
Reakcijska masa je miješana tijekom 2,0 sata.
separating the extract wherein the opioid antagonist is present in said extract in a weight percent amount, based on the total amount of opioid antagonist in the dosage form, that is more than 15 %-points less than the weight percent amount of opioid agonist present in the extract, based on the total amount of opioid agonist in the dosage form, and wherein the opioid agonist is oxycodone hydrochloride and the opioid antagonist is naloxone hydrochloride which are present in the dosage form in an amount ratio of 2:1. 
€) odvajanje ekstrakta gdje je opioidni antagonist prisutan u ekstraktu u količini u težinskom postotku, na temelju ukupne količine opioidnog antagonista u dozirnom obliku, a to je više od 15%-bodova manje od težinskog postotka opioidnog agonista u ekstraktu, na temelju ukupne količine opioidnog agonista u dozirnom obliku, i gdje je opioidni agonist oksikodon hidroklorid, a opioidni antagonist je nalokson hidroklorid, u dozirnom obliku su prisutni u omjeru količina 2:1.
The chosen emulsifier, depending upon its chemical nature, will be a component of either the oil or aqueous phase, and assists with both the formation and the maintenance, or stability, of the emulsion. 
Odabrani emulgator će, ovisno 0 svojoj kemijskoj prirodi, biti komponenta bilo uljne ili vodene faze, i pomaže i kod stvaranja i održavanja, ili stabilnosti, emulzije.
The process according to any one of the preceding claims, wherein coupled to said second side of said sheet material is a further sheet material (102), so as to form a plastically deformable semi-rigid laminar structure. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se s navedenom drugom stranom navedenog materijala za foliju spaja dodatni materijal za foliju (102), kako bi se dobilo polukrutu slojevitu strukturu, koju se može plastično deformirati.
A transdermal therapeutic system comprising a solid dispersion of claim 1 . 
Transdermalni terapijski sustav koji obuhvaća čvrstu disperziju prema patentnom zahtjevu 4 ili 5.
adding to the mixture of a) a pharmaceutically acceptable amount of an acetate salt of caspofungin; 
dodavanje farmaceutski prihvatljive količine acetatne soli kaspofungina smjesi pod a)
The scaffold of claim 1, wherein said biocompatible polymer is in the form of a polymer coating, forming a polymer layer associated with a portion of said scaffold. 
Struktura platforme sukladno patentnom zahtjevu 11, pri čemu spomenuti polimerni premaz, formira polimerni sloj povezan sa dijelom spomenute strukture platforme.
A process according to claim 8 wherein X is introduced in reaction with pyridine and the compound of formula VII is or an acid addition salt or a solvate thereof. 
Postupak prema zahtjevu 8 naznačen time da se X uvodi u reakciju sa piridinom i spoj sa formulom VII je HR P20121026 T1 HO ili njegova kisela adicijska sol ili solvat.
The preferred placement of the guides 23 is outside the sides of the housings 24, substantially in proximity to the ends of the external base compatibly with the insert structure and its tapered configuration. 
Poželjan položaj vodilica 23 je s vanjske strane bočnih strana kućišta 24, uglavnom u blizini krajeva vanjske baze u skladu sa strukturom umetka i njegovim stožastim oblikom.
After complete or partial release of the liquid 4 from the metering chamber 6, the discharge device 1 /metered dose valve 2 can be switched or twisted back into its non-discharge state by relative rotation—preferably in the backwords direction—between the actuation member 17 and the housing/locking element 18 to bypass the second stop 22, i.e., to unlock the second locking means. 
Nakon potpunog ili djelomičnog oslobađanja tekućine 4 iz odmjerne komore 6, napravu za pražnjenje l/ventil za odmjeravanje doze 2 može se prebaciti ili zakrenuti natrag u njezino stanje ne-pražnjenja relativnim okretanjem ponajprije u stražnjem smjeru - između elementa za pokretanje 17 i kućišta/elementa za zabravljivanje 18, tako da se prevlada drugi graničnik 22, tj. da se odbravi drugo sredstvo za zabravljivanje.
The method of claim 1, wherein the essential oil comprises at least one of A-9-tetrahydrocannabinol and A-9-cannabidiol. 
Postupak prema patentnom zahtjevu 1, naznačen time, da esencijalno ulje sadrži najmanje jednu od A-9-tetrahidrokanabinolne kiseline i A-9-kanabidiolne kiseline.
The feed according to claim 15 or 16, wherein the feed is a complete feed or concentrate feed, preferably it is non-extruded and/or in the form of pellets or granulas. 
Krmna smjesa za preživače prema zahtjevu 9 ili 10, pri čemu je hrana potpuna hrana, poželjno neekstrudirana i/ili u obliku peleta ili granula.
is selected from the group consisting of: 
– R2 se bira iz skupine koju čine:
No. 3,773,919 and European Patent Application Publication No. 
Datum podnošenja europske prijave patenta:
Such a program will have functions for controlling the apparatus 1, and management functions, as it will be apparent from the following description (see FIG. 3). 
Takav program će imati funkciju da upravlja s uređajem 1 i da vodi sve funkcije, kao što će to biti jasno iz opisa koji slijedi (vidi sliku 3).
a salt of carbonic acid; and an acidifying agent; wherein the water dispersible fat containing component and the carbon dioxide effervescent component are distinct from each other. 
(b) sredstvo za zakiseljavanje; naznačen time što su komponenta dispergirana u vodi koja sadrži mast i šumeća komponenta ugljikovog dioksida međusobno različite.
provided that when X is CR10 at least one of R7, R8, R9, and R10 is hydrogen. 
uz uvjet da kada je X CR10, najmanje jedan od R7, R8, R9 i R10 je vodik.
wherein in case of a failure of the functionality of the home database, the requesting entity requests the visitor database for the information specific of the User Equipment. 
oda u slučaju onesposobljenosti polazne baze podataka (14), tražitelj usluge (12) od baze podataka o posjetiteljima (11) traži podatke koji su specifični za dotični korisnički uređaj (20).
detecting the formation of the immunologic complex; 
(c) detektiranju formiranja imunološkog kompleksa;
The coating composition of claim 7, wherein the aluminum powder comprises a particle size distribution characterized in that the 50th percentile of the particle size distribution has a diameter of between 3.9 to 4.5 micrometers and the 90th percentile of the particle size distribution has a diameter of less than or equal to 9.0 micrometers. 
Sastav obloge iz patentnog zahtjeva 7, pri čemu prah aluminija obuhvaća raspodjelu veličina čestica karakteriziranu na način da 50. percentila raspodjele veličine čestica ima promjer između 3.9 1 4.5 mikrometara i 90. percentila raspodjele veličine čestica ima promjer manji ili jednak 9.0 mikrometara.
The apparatus of claim 4, wherein the apparatus further comprises; means (301) for outer encoding the PLP data by a Bose-Chadhuri-Hocquenghem, BCH coding scheme; and means (303) for inner encoding the outer encoded PLP data by a Low Density Parity Check, LDPC coding scheme. 
Uređaj iz patentnog zahtjeva 4, pri čemu uređaj nadalje obuhvaća: sredstvo (301) za vanjsko kodiranje PLP podataka pomoću sheme kodiranja Bose-Chadhuri-Hocquenghem, BHC; i sredstvo (303) za unutarnje kodiranje vanjsko kodiranih PLP podataka shemom kodiranja provjere pariteta niske gustoće (LDPC).
A combination according to claim 11, or a combination for use according to claim 12, wherein a inhibitor of TGFB synthesis, for example pirfenidone, is the other pharmaceutically active agent. 
Kombinacija u skladu s patentnim zahtjevom 11, ili kombinacija namijenjena upotrebi u skladu s patentnim zahtjevom 12, naznačena time što je drugo farmaceutski aktivno sredstvo inhibitor sinteze TGFB, primjerice pirfenidon.
A pharmaceutical composition comprising a compound or pharmaceutically-acceptable salt thereof according to any one of claims 1 to 7 and a pharmaceutically-acceptable excipient, carrier, or diluent, optionally wherein the pharmaceutically-acceptable excipient, carrier, or diluent is a solution mixture or suspension mixture comprising, by weight, about 12.5% of DMA, about 52.5% of PEG400, and about 35% of 20% Vitamin E. 
Farmaceutski sastav obuhvaća tvar u skladu s patentnim zahtjevima 1, 2 ili 3 i farmaceutski prihvatljiv ekscipijens, nosač, ili diluent. Farmaceutski sastav iz patentnog zahtjeva 4, pri čemu je farmaceutski prihvatljiv ekscipijens, nosač, ili diluent smjesa u otopini ili smjesa u suspenziji koja obuhvaća, prema masi, oko 12.5% dimetilacetamida, oko 52.5% PEG400 i oko 35% od 20%-tnog vitamina E.
a starting point of the monitoring of the property of the coating is controlled in accordance with a characteristic of the coating process forming the coating; 
polazište praćenja svojstva prevlake se kontrolira u skladu s karakteristikama postupka oblaganja koji nanosi prevlaku;
19 and the three heavy chain CDRs of sequence SEQ ID No. 
19 te tri teška lanca CDRs sekvencije SEQ ID br.
means for converting a transport stream to a Physical Layer Pipe, PLP and generating a data slice including the PLP; 
sredstva za pretvorbu prijenosnog toka u PLP i dobivanje podatkovnog komada, uključujući PLP;
p coated tablet(s) comprising 5 mg of lisinopril or a hydrated form, q coated tablet(s) comprising 10 mg of lisinopril or a hydrated form and r coated tablet(s) comprising 20 mg of lisinopril or a hydrated form, wherein p is an integer chosen from 0 and 1, q is an integer chosen from 0 and 1, and r is an integer chosen from 0, 1 and 2, such that the total amount of lisinopril or hydrated form is from 5 to 40 mg and p+q+r is 1, 2 or 3; or 
p obloženih tableta koje sadrže 5 mg lizinoprila ili hidratnog oblika, q obloženih tableta koje sadrže 10 mg lizinoprila ili hidratnog oblika i r obloženih tableta koje sadrže 20 mg lizinoprila ili hidratnog oblika, gdje p je cijeli broj izabran između 0 i 1, q je cijeli broj izabran između 0 i 1, i r je cijeli broj izabran između 0, 1 i 2, tako da je ukupna količina lizinoprila ili hidratnog oblika od 5 do 40 mg i p+q+r je 1, 2 ili 3; ili
The method according to claim 1, wherein the a-synuclein-related disorder is Parkinson's disease. 
Lijek za uporabu prema zahtjevu 1 ili 2, pri čemu je poremećaj vezan uz a-sinuklein Parkinsonova bolest.
The peptide complex of any one of paragraphs 7-9, wherein the linker moiety comprises the structure Z1-20, wherein Z is an amino acid, hydroxy acid, ethylene glycol, propylene glycol, or a combination of any of the foregoing. 
Peptidni kompleks prema zahtjevu 6, pri čemu ostatak grupe za povezivanje obuhvaća strukturu 21-20, pri čemu Z je aminokiselina, hidroksi kiselina, etilen glikol, propilen glikol, ili bilo koja kombinacija od gore navedenog.
The pharmaceutical composition according to anyone of claims 4 to 8, wherein said composition is in the form of a tablet, capsule, powder, pellet, suspension, emulsion, cream, gel, ointment or paste. 
Farmaceutski pripravak prema patentnom zahtjevu 2 u obliku tablete, kapsule, praška, pilule, suspenzije, emulzije, kreme, gela, masti, losiona, disperzije ili paste.
carboxylic acid amides or carboxylic acid C1-C8-(branched or non-branched) mono or di alkyl amides, such as dimethylamides, diethylamides, di isopropyl amides or e) any other derivative which contains the above imidazolinone structures as structural moiety. 
amide karbonske kiseline ili C1-C8-(razgranate ili nerazgranate) mono- 1li di- alkil amide karbonske kiseline, kao što su dimetilamidi, dietilamidi, diizopropil amidi ili e) bilo koji drugi derivat koji sadrži prethodne strukture imidazolinona kao strukturnu grupu.
A compound according to claim 1, wherein R1 is substituted phenyl, substituted phenylalkyl, substituted phenoxyalkyl, substituted phenylcycloalkyl, substituted phenylalkenyl, substituted phenylalkynyl, substituted pyridinylalkyl, substituted thiophenylalkyl, substituted 2,3-dihydro-1H-isoindol-2-yl, substituted 1H-indol-2-yl or substituted benzofuran-2-yl, wherein substituted phenyl, substituted phenylalkyl, substituted phenoxyalkyl, substituted phenylcycloalkyl, substituted phenylalkenyl, substituted pyridinylalkyl, substituted thiophenylalkyl, substituted 2,3-dihydro-1H-isoindol-2-yl, substituted 1H-indol-2-yl and substituted benzofuran-2-yl are substituted with R8, R9 and R10. 
Spoj prema zahtjevu 1, naznačen time, da R1 je supstituirani fenil, supstituirani fenilalkil, supstituirani fenoksialkil, supstituirani fenilcikloalkil, supstituirani fenilalkenil, supstituirani fenilalkinil, supstituirani piridinilalkil, supstituirani tiofenilalkil, supstituirani 2,3-dihidro-1H-izoindol-2-il, supstituirani 1H-indol-2-il ili supstituirani benzofuran-2-il, pri čemu su supstituirani fenil, supstituirani fenilalkil, supstituirani fenoksialkil, supstituirani fenilcikloalkil, supstituirani fenilalkenil, supstituirani piridinilalkil, supstituirani tiofenilalkil, supstituirani 2,3-dihidro-1H-izoindol-2-il, supstituirani 1H-indol-2-il i supstituirani benzofuran-2-il, supstituirani s R8, R9 i R10.
starting the fermentation of the biomass by setting its temperature to 45-70°C, preferably to 50-60°C, and optionally inoculating the biomass by an inoculum comprising polymer-degrading microorganisms, acetogenic microorganisms and/or methanogenic microorganisms 
- < pokretanje postupka fermentacije biomase postavljanjem njezine temperature na 45-70%C, po mogućnosti na 50-60%C, te opcionalno inokuliranje biomase pomoću inokulanta koji se sastoji od mikroorganizama koji svojim djelovanjem razgrađuju polimere, acetogenih mikroorganizama i/ili metanogenih mikroorganizama,
In particular, it is possible to depress and release the valve element 5 alternately in a “discharge state” to discharge the metered dose of liquid 4 as desired, but without refilling the metering chamber 6 with liquid 4 from the container 3 during this alternate actuation. 
Posebno, element ventila 5 može se po želji pritisnuti 1 osloboditi naizmjenično u "stanje pražnjenja", za pražnjenje odmjerene doze tekućina 4, i to bez ponovnog punjenja odmjerne komore 6 s tekućinom 4 iz spremnika 3 tijekom tog naizmjeničnog pokretanja.
The composition of claims 8 or 9, wherein said composition is in crystalline form, and/or further comprises a pharmaceutically acceptable carrier, preferably in the form of a tablet or capsule. 
Farmaceutski sastav prema patentnom zahtjevu 11, naznačen time, da jest u obliku tablete ili kapsule. Postupak rekristalizacije natrijevog lakvinimoda, naznačen time, da obuhvaća: